Dovitinib multi target TKI  

CHIR-258 - CHIR258 - CHIR 258 - dovitinib - TKI-258 - TKI258 - TKI 258      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

renal-cell carcinoma (advanced)  

GOLD      NCTdovitinibsorafenibRisk of bias negative-14%